Abstract
Objective: To describe for surgeons contemplating performing cytoreductive nephrectomy (CRN) on patients after neoadjuvant sunitinib compared to a benchmark of open radical nephrectomy, describing technical difficulties, safety and feasibility. Patients and Methods: We compared measurable surgical parameters and perioperative complications in 22 patients with metastatic renal cell carcinoma (mRCC) undergoing CRN after neoadjuvant sunitinib, with 28 patients who underwent open radical nephrectomy for non-metastatic disease (nmRCC). Results: Median blood loss (320 vs. 775 ml), median operative time (128 vs. 195 min) and median length of stay (5 vs. 7 days) were greater in the mRCC group. Surgery after sunitinib was technically challenging due to fibrosis, loss of the tissue planes that usually facilitate radical nephrectomy and abnormal blood vessel formation. Side effects of sunitinib resulted in predictable complications. Conclusion: CRN after treatment with sunitinib is safe and feasible in our hands, although the surgery is more time-consuming and technically demanding. A multidisciplinary approach is mandatory.
Journal Section:
Editor's choice
References
1.
Kovacs G, Akhtar M, Beckwith BJ, et al: The Heidelberg classification of renal cell tumours. J Pathol 1997;183:131–133.
[PubMed]
2.
Office for National Statistics. Cancer Statistics Registrations: Registrations of cancer diagnosed in 2007, England. Series MB1 No. 38. 2010, National Statistics: London and Mortality Statistics: 2008. Available from www.statistics.gov.uk.
3.
Bex A, Jonasch E, Kirkali Z, et al: Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol 2010;58:819–828.
4.
Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–124.
[PubMed]
5.
Tomlins SA, Rhodes DR, Perner S, et al: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644–648.
[PubMed]
6.
Flanigan RC, Salmon SE, Blumenstein BA, et al: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655–1659.
[PubMed]
7.
Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966–970.
[PubMed]
8.
Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED: Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071–1076.
[PubMed]
9.
Abel EJ, Wood CG: Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat Rev Urol 2009;6:375–383.
10.
Slaton JW, Inoue K, Perrotte P, et al: Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 2001;158:735–743.
[PubMed]
11.
Josephs D, Hutson TE, Cowey CL, et al: Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int 2011;108:1279–1283.
12.
Roman CD, Choy H, Nanney L, et al: Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res 2002;105:43–47.
[PubMed]
13.
Margulis V, Matin SF, Tannir N, et al: Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 2008;180:94–98.
[PubMed]
14.
Thomas AA, Rini BI, Stephenson AJ, et al: Surgical resection of renal cell carcinoma after targeted therapy. J Urol 2009;182:881–886.
15.
Harshman LC, Yu RJ, Allen GI, Srinivas S, Gill HS, Chung BI: Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma. Urol Oncol 2011, E-pub ahead of print.
© 2012 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2012
You do not currently have access to this content.
